Here's Why Celltrion (KRX:068270) Can Manage Its Debt Responsibly
Feb 14
Have your own idea? Try our Stock Screener
South Korean (KOSPI) Healthcare Sector Analysis
UpdatedFeb 14, 2026
DataAggregated Company Financials
Companies370
- 7D4.1%
- 3M10.4%
- 1Y26.4%
- YTD6.2%
The Healthcare industry is up 4.1% in the last week, with Celltrion up 8.2%. In the same time, Kolon TissueGene was down 5.1%. This means that the industry has gained 26% over the past year. As for the next few years, earnings are expected to grow by 36% per annum.
Sector Valuation and Performance
Has the South Korean Healthcare Sector valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 14 Feb 2026 | ₩391.9t | ₩61.0t | ₩2.7t | 19.6x | 145.4x | 6.4x |
| Mon, 12 Jan 2026 | ₩389.6t | ₩61.9t | ₩2.7t | 18.4x | 144.1x | 6.3x |
| Wed, 10 Dec 2025 | ₩358.8t | ₩61.7t | ₩2.8t | 19.4x | 129.2x | 5.8x |
| Fri, 07 Nov 2025 | ₩332.6t | ₩60.4t | ₩2.1t | 19.8x | 157x | 5.5x |
| Sun, 05 Oct 2025 | ₩305.6t | ₩60.3t | ₩2.1t | 20.8x | 147.7x | 5.1x |
| Tue, 02 Sep 2025 | ₩287.6t | ₩60.0t | ₩1.9t | 20.5x | 149.6x | 4.8x |
| Thu, 31 Jul 2025 | ₩299.2t | ₩58.3t | ₩1.5t | 21.5x | 205.5x | 5.1x |
| Sat, 28 Jun 2025 | ₩273.6t | ₩58.0t | ₩1.5t | 21.1x | 186.6x | 4.7x |
| Mon, 26 May 2025 | ₩265.1t | ₩57.3t | ₩1.6t | 22.4x | 165.3x | 4.6x |
| Wed, 23 Apr 2025 | ₩270.1t | ₩56.1t | ₩1.3t | 18.4x | 201.4x | 4.8x |
| Fri, 21 Mar 2025 | ₩272.5t | ₩55.1t | ₩858.2b | 14.5x | 317.5x | 4.9x |
| Sun, 16 Feb 2025 | ₩284.5t | ₩54.7t | ₩916.4b | 15x | 310.5x | 5.2x |
| Tue, 14 Jan 2025 | ₩266.6t | ₩54.5t | ₩840.5b | 14.9x | 317.2x | 4.9x |
| Thu, 12 Dec 2024 | ₩249.9t | ₩54.3t | ₩800.3b | 13.3x | 312.3x | 4.6x |
| Sat, 09 Nov 2024 | ₩269.6t | ₩53.1t | ₩815.2b | 16.1x | 330.7x | 5.1x |
| Mon, 07 Oct 2024 | ₩271.2t | ₩53.3t | ₩838.0b | 16.9x | 323.7x | 5.1x |
| Wed, 04 Sep 2024 | ₩266.9t | ₩53.4t | ₩855.9b | 17.2x | 311.8x | 5x |
| Fri, 02 Aug 2024 | ₩258.9t | ₩52.3t | ₩750.8b | 16.2x | 344.9x | 5x |
| Sun, 30 Jun 2024 | ₩224.4t | ₩52.7t | ₩742.9b | 16.7x | 302.1x | 4.3x |
| Tue, 28 May 2024 | ₩222.7t | ₩52.8t | ₩727.7b | 17.1x | 306x | 4.2x |
| Thu, 25 Apr 2024 | ₩234.0t | ₩52.3t | ₩538.5b | 17.9x | 434.5x | 4.5x |
| Sat, 23 Mar 2024 | ₩246.6t | ₩52.3t | ₩114.9b | 20.1x | 2145.6x | 4.7x |
| Mon, 19 Feb 2024 | ₩224.7t | ₩52.0t | -₩48,458,490,006.00 | 23.5x | -4637.3x | 4.3x |
| Wed, 17 Jan 2024 | ₩238.4t | ₩56.1t | ₩268.5b | 23.3x | 887.9x | 4.2x |
| Fri, 15 Dec 2023 | ₩212.2t | ₩56.1t | ₩280.7b | 21.6x | 756x | 3.8x |
| Sun, 12 Nov 2023 | ₩205.1t | ₩56.0t | ₩1.0t | 18.3x | 199.4x | 3.7x |
| Tue, 10 Oct 2023 | ₩207.0t | ₩56.0t | ₩1.0t | 18.6x | 202.2x | 3.7x |
| Thu, 07 Sep 2023 | ₩214.2t | ₩56.0t | ₩932.5b | 20x | 229.7x | 3.8x |
| Sat, 05 Aug 2023 | ₩217.3t | ₩56.1t | ₩2.1t | 22.3x | 104x | 3.9x |
| Mon, 03 Jul 2023 | ₩207.2t | ₩56.1t | ₩2.1t | 20.8x | 98.4x | 3.7x |
| Wed, 31 May 2023 | ₩215.2t | ₩56.5t | ₩2.1t | 21.2x | 100.1x | 3.8x |
| Fri, 28 Apr 2023 | ₩210.6t | ₩58.4t | ₩3.2t | 19.6x | 64.8x | 3.6x |
| Sun, 26 Mar 2023 | ₩202.3t | ₩58.1t | ₩4.0t | 18.2x | 50.4x | 3.5x |
| Tue, 21 Feb 2023 | ₩208.7t | ₩57.8t | ₩4.6t | 18.3x | 45.3x | 3.6x |
Price to Earnings Ratio
45.3x
Current Industry PE
- Investors are pessimistic on the South Korean Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 145x which is lower than its 3-year average PE of 279x.
- The 3-year average PS ratio of 4.6x is lower than the industry's current PS ratio of 6.4x.
Past Earnings Growth
- The earnings for companies in the Healthcare industry have declined 16% per year over the last three years.
- Meanwhile revenues have remained mostly flat.
- This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the South Korean Healthcare sector?
| KR Market | 7.56% | |
| Healthcare | 4.14% | |
| Healthtech | 8.18% | |
| Biotech | 5.67% | |
| Pharma | 4.49% | |
| Life Sciences | 2.53% | |
| Medical Equipment | 1.24% | |
| Healthcare Services | -4.20% | |
Industry PE
- Investors are most optimistic about the Biotech industry which is trading above its 3-year average PE ratio.
- Analysts expect its future annual earnings growth (43.0%) to be largely in line with prior year's earnings growth.
Forecasted Growth
- Analysts are most optimistic on the Medical Equipment industry, expecting annual earnings growth of 52% over the next 5 years.
- This is better than its past earnings growth rate of 16% per year.
- In contrast, the Healthtech industry is expected to see its earnings decline by 31% per year over the next few years.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| A068270 Celltrion | ₩238.00k | 8.2% +₩4.0t | 36.9% | PE70.6x | |
| A207940 Samsung BiologicsLtd | ₩1.71m | 2.5% +₩1.9t | -5.7% | PE49x | |
| A196170 ALTEOGEN | ₩382.00k | 5.8% +₩1.1t | -3.0% | PE162.2x | |
| A0126Z0 Samsung Epis Holdings | ₩603.00k | 8.1% +₩1.1t | n/a | n/a | |
| A000250 Sam Chun Dang Pharm | ₩535.00k | 7.0% +₩814.0b | 205.4% | PS56.4x |
